SCHEMBL23639725

SCHEMBL23639725

CN(CCC(C)(C)CCC(C)(C)CCC(=O)N(C)CCC(C)(C)CCC(C)(C)CC(=O)N(C)CCC(C)(C)C)C(=O)CCCC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22021679 0.84 EPHX2 (0.36) —
SCHEMBL22021900 0.80 EPHX2 (0.36) —
SCHEMBL22021658 0.77 EPHX2 (0.41) —
SCHEMBL22021685 0.77 EPHX2 (0.41) —
SCHEMBL22021680 0.77 EPHX2 (0.41) —
SCHEMBL22021683 0.77 NAMPT (0.32) —
SCHEMBL12793200 0.73 EPHX2 (0.36) —
SCHEMBL17662444 0.73 ALDH1A1 (0.33) —
SCHEMBL22021691 0.73 EPHX2 (0.50) —
SCHEMBL23639935 0.72 EPHX2 (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210213012-A1 COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER ACCUTAR BIOTECHNOLOGY INC. 2021-07-15 — — US disclosed
Send feedback